Final-Program-ATS-2023-AP.vp

WEDNESDAY • MAY 24

347

609 VQ-SPECT/CT Following Recovery From Non-critical COVID-19: 6 Month Longitudinal Follow-up/ C. Venegas Garrido, Hamilton, Canada 610 Post-acute COVID-19 Imaging Abnormalities on Hyperpolarized 129 Xe MRI Persist Over 6 Months/ P.J. Niedbalski, Kansas City, KS 611 Assessment of Gas Exchange in Long COVID Using Hyperpolarized 129-Xenon MRI and Dual Energy CT/ A.D. Hahn, Iowa City, IA 612 Th17 Overexpression In Severe COVID-19 Pneumonia: A Prospective Observational Study/ A. Gupta, New Delhi, India 613 Increased Intrapulmonary Shunt and Alveolar Dead Space in Patients Recovered From COVID-19 Pneumonitis/ K. Kairaitis, Westmead, Australia 614 Longitudinal Assessment of Lung Function in COVID-19 Patients/ D.A. Kaminsky, Burlington, VT 615 Long COVID-19 Severity and Its Impacts on Pulmonary Function A 1 Year Follow-Up Study/ G.D. Back, Sao Carlos, Brazil 616 A Descriptive Study of Pulmonary Function Parameters and Respiratory Muscle Strength in Long COVID-19 Patients With Pre-existing Asthma/ K. Sankar, Los Angeles, CA 617 Pulmonary Function Testing in Post-Acute Sequelae From COVID-19/ C. Walker, Washington, DC 618 Clinical Significance of Asymmetric Lung Injury in ARDS in COVID-19/ I. Barjaktarevic, Los Angeles, CA

922 C5a Anaphylatoxin Receptor 1 Mediates Pleural Hypertrophy and Rheumatoid Lung Fibrosis in Collagen-induced Arthritic Mice/ P. Shivshankar, Houston, TX 923 Defining the Pathogenic Role of Neural Crest Cells in Lymphangioleiomyomatosis: Mechanistic and Therapeutic Implications/ U.J. Unachukwu, New York, NY 924 Divergent Lung Tissue Methylation Signatures of COPD and Pulmonary Fibrosis/ K.H. Shutta, Boston, MA 925 Discovery of G-protein Biased APJ Agonist Small Molecule for Pulmonary Diseases/ S. Shi, South San Francisco, CA D109 THE LONG AND THE SHORT OF LONG COVID 12:00 p.m. - 2:00 p.m. Walter E. Washington Convention Center Room 201 (Level 2) Poster Viewing 12:00-12:45 Discussion 12:45-2:00 Chairing: R.G. Jenkins, BM, MD, MRCP(UK), PhD, London, United Kingdom R.G. Scheraga, MD, ATSF, Cleveland, OH 601 Unique MRI Phenotypes Help Explain Post-Acute COVID-19 Syndrome/ J.M. Nicholson, London, Canada 602 129Xe Magnetic Resonance Imaging-based Phenotypes of Long COVID: A Multi-center Evaluation/ R.L. Eddy, Vancouver, Canada 603 Airway Mucosal Abnormalities in Post-COVID-19 Patients With Persistent Pulmonary Symptoms: Results From Single-cell RNA-sequencing/ F.V. Gerayeli, Vancouver, Canada 604 Long-COVID Is Associated With Residual Functional Small Airway Disease and Parenchymal Changes Regardless of SARS-CoV-2 Variant/ R.A. Tudas, Iowa City, IA 605 Evolution of Symptoms and Lung Function After SARS-CoV-2 Infection/ D. Collazo, New York, NY 606 Changes in the Human Lung Extracellular Matrix Proteome After SARS-CoV-2 Infection/ J.A. Huapaya, Bethesda, MD 607 Sex Differences in CT Airway Measurements and Their Relationship to Post-Acute COVID-19 Syndrome/ H.K. Kooner, London, Canada 608 One-fourth of COVID-19 Patients Have an Impaired Pulmonary Function After 12 Months of Illness Onset/ H. Willigen, Amsterdam, Netherlands BASIC • CLINICAL • TRANSLATIONAL POSTER DISCUSSION SESSION

ATS 2023 • Washington, DC